The online version of this article (doi:10.1186/cc9308) contains supplementary material, which is available to authorized users.
CJW has received speaker fees and travel reimbursements from manufacturers of plasma-derived therapies (CSL Behring, King of Prussia, PA, USA, and Kedrion, Prato, Italy). The other authors declare that they have no competing interests.
CJW conceived the meta-analysis and participated in its design and coordination, extracted data, performed statistical analysis, contributed to the interpretation of results, and helped to draft the manuscript. MJ participated in the design and coordination of the meta-analysis, contributed to the interpretation of results, and helped to draft the manuscript. All authors participated in searching for trials and determining their eligibility for inclusion in the meta-analysis. All authors read and approved the final manuscript.
It has been hypothesized that hyperoncotic colloids might contribute to acute kidney injury (AKI). However, the validity of this hypothesis remains unclear.
A meta-analysis was conducted of randomized controlled trials evaluating AKI after infusion of hyperoncotic albumin and hydroxyethyl starch (HES) solutions. Mortality was a secondary endpoint. Eligible trials were sought by multiple methods, and the pooled odds ratios (OR) for AKI and death and 95% confidence intervals (CI) were computed under a random effects model.
Eleven randomized trials with a total of 1220 patients were included: 7 evaluating hyperoncotic albumin and 4 hyperoncotic HES. Clinical indications were ascites, surgery, sepsis and spontaneous bacterial peritonitis. Hyperoncotic albumin decreased the odds of AKI by 76% (OR, 0.24; CI, 0.12-0.48; P < 0.0001), while hyperoncotic HES increased those odds by 92% (OR, 1.92; CI, 1.31-2.81; P = 0.0008). Parallel effects on mortality were observed, with hyperoncotic albumin reducing the odds of death by 48% (OR, 0.52; CI, 0.28-0.95; P = 0.035) and hyperoncotic HES raising those odds by 41% (OR, 1.41; CI, 1.01-1.96; P = 0.043).
This meta-analysis does not support the hypothesis that hyperoncotic colloid solutions per se injure the kidney. Renal effects appear instead to be colloid-specific, with albumin displaying renoprotection and HES showing nephrotoxicity.
Dart AB, Mutter TC, Ruth CA, Taback SP: Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2010, 1: CD007594. PubMed
Zarychanski R, Turgeon AF, Fergusson DA, Cook DJ, Hébert P, Bagshaw SM, Monsour D, McIntyre L: Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials. Open Med 2009, 3: 196-209.
Joannidis M, Druml W, Forni LG, Groeneveld AB, Honore P, Oudemans-van Straaten HM, Ronco C, Schetz MR, Woittiez AJ: Prevention of acute kidney injury and protection of renal function in the intensive care unit Expert opinion of the working group for nephrology, ESICM. Intensive Care Med 2010, 36: 392-411. 10.1007/s00134-009-1678-y CrossRefPubMed
Baylis C, Ichikawa I, Willis WT, Wilson CB, Brenner BM: Dynamics of glomerular ultrafiltration. IX. Effects of plasma protein concentration. Am J Physiol 1977, 232: F58-71. PubMed
Cabrales P, Intaglietta M, Tsai AG: Increase plasma viscosity sustains microcirculation after resuscitation from hemorrhagic shock and continuous bleeding. Shock 2005, 23: 549-555. PubMed
Ginès P, Titó L, Arroyo V, Planas R, Panés J, Viver J, Torres M, Humbert P, Rimola A, Llach J, Badalamenti S, Jiménez W, Gaya J, Rodés J: Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988, 94: 1493-1502. PubMed
London MJ, Ho JS, Triedman JK, Verrier ED, Levin J, Merrick SH, Hanley FL, Browner WS, Mangano DT: A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. J Thorac Cardiovasc Surg 1989, 97: 785-797. PubMed
Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Ginès P, Rodés J: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341: 403-409. 10.1056/NEJM199908053410603 CrossRefPubMed
Sola-Vera J, Miñana J, Ricart E, Planella M, González B, Torras X, Rodríguez J, Such J, Pascual S, Soriano G, Pérez-Mateo M, Guarner C: Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003, 37: 1147-1153. 10.1053/jhep.2003.50169 CrossRefPubMed
Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008, 358: 125-139. 10.1056/NEJMoa070716 CrossRefPubMed
Chen T-A, Tsao Y-C, Chen A, Lo G-H, Lin C-K, Yu H-C, Cheng L-C, Hsu P-I, Tsai W-L: Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol 2009, 44: 619-625. 10.1080/00365520902719273 CrossRefPubMed
Brochard L, Abroug F, Brenner M, Broccard AF, Danner RL, Ferrer M, Laghi F, Magder S, Papazian L, Pelosi P, Polderman KH: An Official ATS/ERS/ESICM/SCCM/SRLF Statement: Prevention and Management of Acute Renal Failure in the ICU Patient: an international consensus conference in intensive care medicine. Am J Respir Crit Care Med 2010, 181: 1128-1155. 10.1164/rccm.200711-1664ST CrossRefPubMed
Kaufmann MA, Castelli I, Pargger H, Drop LJ: Nitric oxide dose-response study in the isolated perfused rat kidney after inhibition of endothelium-derived relaxing factor synthesis: the role of serum albumin. J Pharmacol Exp Ther 1995, 273: 855-862. PubMed
Levine JS, Koh JS, Triaca V, Lieberthal W: Lysophosphatidic acid: a novel growth and survival factor for renal proximal tubular cells. Am J Physiol 1997, 273: F575-585. PubMed
Dixon R, Brunskill NJ: Activation of mitogenic pathways by albumin in kidney proximal tubule epithelial cells: implications for the pathophysiology of proteinuric states. J Am Soc Nephrol 1999, 10: 1487-1497. PubMed
Iglesias J, Abernethy VE, Wang Z, Lieberthal W, Koh JS, Levine JS: Albumin is a major serum survival factor for renal tubular cells and macrophages through scavenging of ROS. Am J Physiol 1999, 277: F711-722. PubMed
Romanelli RG, La Villa G, Barletta G, Vizzutti F, Lanini F, Arena U, Boddi V, Tarquini R, Pantaleo P, Gentilini P, Laffi G: Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 2006, 12: 1403-1407. PubMedCentralPubMed
Contreras AM, Ramírez M, Cueva L, Alvarez S, de Loza R, Gamba G: Low serum albumin and the increased risk of amikacin nephrotoxicity. Rev Invest Clin 1994, 46: 37-43. PubMed
Pockaj BA, Yang JC, Lotze MT, Lange JR, Spencer WF, Steinberg SM, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA: A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. J Immunother Emphasis Tumor Immunol 1994, 15: 22-28. 10.1097/00002371-199401000-00003 CrossRefPubMed
Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, Lauchart W, Peszynski P, Freytag J, Hickstein H, Loock J, Löhr J-M, Liebe S, Emmrich J, Korten G, Schmidt R: Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000, 6: 277-286. 10.1053/lv.2000.6355 CrossRefPubMed
Lukasewitz P, Kroh U, Löwenstein O, Krämer M, Lennartz H: Quantitative investigations of tissue accumulation of intermediate molecular weight hydroxyethyl starch in patients with multiple organ failure. J Anaesth Intensivbeh 1998, 3: 42-46.
Peron S, Mouthon L, Guettier C, Brechignac S, Cohen P, Guillevin L: Hydroxyethyl starch-induced renal insufficiency after plasma exchange in a patient with polymyositis and liver cirrhosis. Clin Nephrol 2001, 55: 408-411. PubMed
Hagne C, Schwarz A, Gaspert A, Giambarba C, Keusch G: HAES in septic shock - sword of Damocles? Schweiz Med Forum 2009, 9: 304-306.
Nagy KK, Davis J, Duda J, Fildes J, Roberts R, Barrett J: A comparison of pentastarch and lactated Ringer's solution in the resuscitation of patients with hemorrhagic shock. Circ Shock 1993, 40: 289-294. PubMed
Boldt J, Brosch C, Röhm K, Lehmann A, Mengistu A, Suttner S: Is albumin administration in hypoalbuminemic elderly cardiac surgery patients of benefit with regard to inflammation, endothelial activation, and long-term kidney function? Anesth Analg 2008, 107: 1496-1503. 10.1213/ane.0b013e31818370b2 CrossRefPubMed
Hüter L, Simon TP, Weinmann L, Schuerholz T, Reinhart K, Wolf G, Amann KU, Marx G: Hydroxyethylstarch impairs renal function and induces interstitial proliferation, macrophage infiltration and tubular damage in an isolated renal perfusion model. Crit Care 2009, 13: R23. 10.1186/cc7726 PubMedCentralCrossRefPubMed
- Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials
Christian J Wiedermann
Luigi U Gaioni
- BioMed Central
Neu im Fachgebiet AINS
Meistgelesene Bücher aus dem Fachgebiet AINS
Mail Icon II